Author

Fiona Richardson Page 5

Fiona Richardson is a cancer biologist who directs a research laboratory at an academic oncology center in Roswell, New Mexico. For 11 years, she has investigated cellular signaling pathways, studying how specific genetic mutations alter tumor growth and influence response to targeted pharmaceuticals and immunotherapy. Richardson graduated from Yale University with a doctorate in cancer biology after undergraduate studies in biochemistry. She carried out post-doctoral translational research on targeted oncogenic pathways, and on weekends she volunteers as a judge for regional student science fairs.

How the HPV E7 Oncoprotein Causes Cancer Cancer
The RPMI 8226 Multiple Myeloma Cell Line Cancer
What Are the iRECIST Criteria for Immunotherapy?Tests
SOD2 and Cancer: The Enzyme’s Role in Tumor Metabolism Cancer
Cbl-b Inhibitor Approaches for Future Immune Therapies Cancer
EMT6 Tumor Cells: Current Insights and Radiotherapy Response Cancer
Cancer Stem Cell Markers: Roles in Tumor Development and Spread Cancer
Metastatic Cascade: Key Stages and Molecular Drivers Cancer
Necrotic Metastasis: Impact on Tumor Progression Cancer
CD68 Positive Cells and Their Impact on Cancer Prognosis Cancer
Gliotoxin Therapy: Mechanisms, Targets, and Delivery Strategies Drugs
How L858R Alters Lung Cancer Growth and Division Cancer
ADC Bystander Effect: Mechanism and Tumor Microenvironment Cancer
Exon 20: The Role of EGFR Insertions in Lung Cancer Cancer
BRD4 Inhibitor in Cancer Treatments: Mechanisms and Impact Cancer
KRAS G12R Mutation: Clinical Relevance and Detection Methods Genetics
HCC1806: Phenotypic Insights and Molecular Discoveries Cancer
KRAS G12V: New Insights in Cancer Biology Cancer
Orthotopic vs Subcutaneous Tumor Model: Key Insights Cancer
Tumor Stromal Cells: Roles in Cancer Progression Cancer
CT26 Tumor Model: Advancing Research in Immunotherapy Cancer